Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents

被引：2
|
作者：
Cook, G. [1 ]
机构：
[1] Univ Leeds, Dept Haematol, Transplant Immunol Grp, Sect Expt Haematol,Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
来源：
BONE MARROW TRANSPLANTATION | 2015年 / 50卷 / 10期
关键词：
HIGH-DOSE MELPHALAN; BORTEZOMIB; DEXAMETHASONE; THERAPY; PHASE-2; RELAPSE; TRIAL;
D O I：
10.1038/bmt.2015.175
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：1269 / 1270
页数：2
相关论文
共 50 条
  • [41] A Comparison of the Outcomes of Early Versus Delayed Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies
    Leng, Siyang
    Moshier, Erin
    Tremblay, Douglas
    Biran, Noa
    Barman, Naman
    Jagannath, Sundar
    Chari, Ajai
    BLOOD, 2015, 126 (23)
  • [42] Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
    Jimenez-Zepeda, Victor H.
    Mikhael, Joseph
    Winter, Andrew
    Franke, Norman
    Masih-Khan, Esther
    Trudel, Suzanne
    Chen, Christine
    Kukreti, Vishal
    Reece, Donna E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (05) : 773 - 779
  • [43] A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents
    Chakraborty, Rajshekhar
    Muchtar, Eli
    Kumar, Shaji
    Jevremovic, Dragan
    Buadi, Francis K.
    Dingli, David
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Hogan, William J.
    Kapoor, Prashant
    Lacy, Martha Q.
    Leung, Nelson
    Gertz, Morie A.
    BLOOD, 2016, 128 (22)
  • [44] Cytomegalovirus Reactivation Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Chemotherapeutics and Tandem Transplantation
    Kim, Jong Hun
    Goulston, Claudia
    Sanders, Stephanie
    Lampas, Mary
    Zangari, Maurizio
    Tricot, Guido
    Hanson, Kimberly E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (11) : 1753 - 1758
  • [45] THE IMPACT OF THE NOVEL THERAPIES BEFORE AND AFTER FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
    Min, C. K.
    Lee, S. E.
    Yang, S.
    Cho, B. S.
    Eom, K. S.
    Kim, Y. J.
    Lee, S.
    Kim, H. J.
    Cho, S. G.
    Kim, D. W.
    Lee, J. W.
    Min, W. S.
    Park, J. W.
    HAEMATOLOGICA, 2012, 97 : 611 - 612
  • [46] The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma
    Joks, Monika
    Jurczyszyn, Artur
    Machaczka, Maciej
    Skotnicki, Aleksander B.
    Komarnicki, Mieczyslaw
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (02) : 109 - 114
  • [47] Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents
    Al-Hamadani, Mohammed
    Hashmi, Shahrukh K.
    Go, Ronald S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (08) : 825 - 830
  • [48] A Revised International Staging System of Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation in Japan: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma
    Ozaki, Shuji
    Saitoh, Takayuki
    Handa, Hiroshi
    Murakami, Hirokazu
    Suzuki, Kenshi
    Takezako, Naoki
    Konishi, Jun
    Sunami, Kazutaka
    Kuroda, Yoshiaki
    Itagaki, Mitsuhiro
    Asaoku, Hideki
    Nagura, Eiichi
    Shimizu, Kazuyuki
    BLOOD, 2015, 126 (23)
  • [49] AUTOLOGOUS STEM CELLS TRANSPLANTATION AFTER USE OF NOVEL AGENTS AS SALVAGE TREATMENT FOR PATIENTS WITH MULTIPLE MYELOMA RELAPSED AFTER FIRST AUTOGRAFT
    Donnini, I.
    Nozzoli, C.
    Di Gioia, M.
    Staderini, M.
    Antonioli, E.
    Bacchiarri, F.
    Guidi, S.
    Bosi, A.
    HAEMATOLOGICA, 2015, 100 : 177 - 178
  • [50] Early lymphocyte recovery (ELR) impact on disease outcome following autologous hematopoietic stem cell transplantation (HDT/ASCT) for multiple myeloma (MM) in the era of novel agents.
    McDuffie, Jeremy Scott
    Savani, Bipin N.
    Chinratanalab, Wichai
    Goodman, Stacey
    Greer, John P.
    Oluwole, Olalekan O.
    Engelhardt, Brian G.
    Jagasia, Madan H.
    Kassim, Adetola
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345